Log in
Enquire now
‌

CFD RESEARCH CORPORATION SBIR Phase I Award, September 2022

A SBIR Phase I contract was awarded to CFD Research Corporation in September, 2022 for $300,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health.

OverviewStructured DataIssuesContributors

Contents

sbir.gov/node/2340615
Is a
SBIR/STTR Awards
SBIR/STTR Awards

SBIR/STTR Award attributes

SBIR/STTR Award Recipient
CFD Research Corporation
CFD Research Corporation
0
Government Agency
0
Government Branch
National Institutes of Health
National Institutes of Health
0
Award Type
SBIR0
Contract Number (US Government)
1R43EY034422-010
Award Phase
Phase I0
Award Amount (USD)
300,0000
Date Awarded
September 1, 2022
0
End Date
August 31, 2023
0
Abstract

Project Summary/Abstract: The overall objective of this study is to develop a novel, predictive in vitro platform for studying physiological responses of the cellular layers of the anterior eye for therapeutics. Current in vitro models mostly rely on a single cellular architecture of the corneal epithelium and do not mimic the in vivo physiological relevance of cell-cell and cell-ECM interactions. In addition, they lack the capability for real-time visualization and quantitation of cellular interactions. Animal models do not accurately represent the anatomy and physiology of the human eye. We propose to develop and demonstrate a microfluidic-based multicellular architecture of the human cornea based on in vivo morphological and structural parameters. Phase I will culminate with a clear demonstration on the ability of the model to match drug penetration profiles with detailed functional characterization of the cellular interactions and matrix development. During Phase II, we will expand the platform to incorporate additional tissue layers such as the conjunctiva and integration with well plates for a multiplexed assay followed by further validation against in vivo studies. A multi-disciplinary, partnership with expertise in microfluidic cell-based assays, eye physiology and therapeutic screening with clinical relevance has been assembled to successfully meet the research objectives. The end-product will be commercialized to pharmaceutical firms, drug research labs and universities/non-profit centers engaged in precision therapeutics, drug discovery, and drug delivery in the ophthalmic space.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like CFD RESEARCH CORPORATION SBIR Phase I Award, September 2022

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.